# Episode 66: Mark Abelson, Founder of Ora Clinical

Page: https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-66-mark-abelson-founder-of-ora-clinical
Text version: https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-66-mark-abelson-founder-of-ora-clinical.md
Podcast: [Few & Far Between: How Biotech Gets Built](https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896)
Published: 2025-12-16T10:20:00+00:00
Episode link: https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-66-mark-abelson-founder-of-ora-clinical
Audio file: https://dts.podtrac.com/redirect.mp3/episodes.castos.com/6026d270a471b8-76273800/2290812/c1e-o3p3nb28qg5im2roj-jpn5g0rwi7p3-bkrcrf.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-66-mark-abelson-founder-of-ora-clinical
Duration seconds: 2607

## Resource

Are clinical trial protocols a true art form? Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes guest Mark Ableson, founder of Ora Clinical and CRO pioneer. We'll be discussing exploratory endpoints, what to learn from failed trails, and essential factors in choosing a clinical site location. Listen today!

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-66-mark-abelson-founder-of-ora-clinical/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-66-mark-abelson-founder-of-ora-clinical.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.